Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Hold” by Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned an average recommendation of “Hold” from the twenty-three ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.4565.

Several brokerages recently commented on NTLA. Sanford C. Bernstein upped their target price on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Chardan Capital upped their target price on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Morgan Stanley upped their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research report on Monday, April 27th. restated a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. Finally, Leerink Partners set a $35.00 price target on Intellia Therapeutics in a report on Monday, April 27th.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $15.67 on Friday. Intellia Therapeutics has a one year low of $7.95 and a one year high of $28.25. The stock’s 50-day moving average is $13.74 and its 200 day moving average is $12.50. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -4.43 and a beta of 1.92.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The company had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter in the prior year, the company earned ($1.10) EPS. On average, sell-side analysts expect that Intellia Therapeutics will post -3.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farallon Capital Management LLC purchased a new stake in shares of Intellia Therapeutics in the third quarter worth approximately $10,486,000. Vanguard Group Inc. raised its stake in shares of Intellia Therapeutics by 1.8% in the third quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock worth $190,744,000 after purchasing an additional 192,651 shares during the last quarter. Jupiter Asset Management Ltd. purchased a new stake in shares of Intellia Therapeutics in the third quarter worth approximately $23,519,000. Contrarius Group Holdings Ltd raised its stake in shares of Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after purchasing an additional 4,337,428 shares during the last quarter. Finally, Wesbanco Bank Inc. purchased a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $575,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.